8-K: Apellis Reports Strong 2025 Revenue, SYFOVRE Growth

Apellis Pharmaceuticals announced preliminary 2025 U.S. net product revenues of $689 million, driven by strong SYFOVRE demand and EMPAVELI's successful launch, positioning the company for profitability.

Summary

• Preliminary unaudited total U.S. net product revenues for the full year 2025 reached approximately $689 million.
• SYFOVRE generated approximately $587 million in U.S. net product revenues for full-year 2025 and $155 million in Q4 2025.
• EMPAVELI generated approximately $102 million in U.S. net product revenues for full-year 2025 and $35 million in Q4 2025.
• SYFOVRE total injection demand grew 17% year-over-year and maintained approximately 60% market share in geographic atrophy (GA) in Q4 2025.
• EMPAVELI achieved 267 new patient start forms in 2025, reaching over 5% market penetration in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) within five months post-launch.
• Year-end cash and cash equivalents were approximately $466 million as of December 31, 2025.
• The company expects current cash and projected revenues to be sufficient to fund operations to profitability.
• A regulatory submission for SYFOVRE prefilled syringe is planned for the first half of 2026.
• Pivotal trials were initiated for EMPAVELI in focal segmental glomerulosclerosis (FSGS) and delayed graft function (DGF).
• An Investigational New Drug (IND) submission for APL-90993, a potential one-time neonatal Fc receptor (FcRn) treatment, is planned for the second half of 2026.

Sentiment

Score: 8

Explanation: The filing presents strong preliminary financial results, significant commercial progress for both key products (SYFOVRE and EMPAVELI), and a robust pipeline with clear next steps. The company's confidence in self-funding to profitability and maintaining market leadership for SYFOVRE are highly positive indicators, despite the inherent risks of the pharmaceutical industry.

Positives

• Strong preliminary full-year 2025 U.S. net product revenues of $689 million.
• SYFOVRE injection demand grew 17% year-over-year.
• SYFOVRE maintained a clear market leader position in GA with approximately 60% total market share in Q4 2025.
• EMPAVELI's strong launch in C3G and primary IC-MPGN with 267 new patient start forms in 2025, achieving over 5% market penetration.
• Rapid payer uptake for EMPAVELI with 95% of policies covering to label or with minimal restrictions.
• Positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for Aspaveli (systemic pegcetacoplan) in C3G and primary IC-MPGN.
• Initiation of pivotal trials for EMPAVELI in two additional nephrology indications (FSGS and DGF).
• Preliminary year-end cash and cash equivalents of approximately $466 million.
• The company projects current cash and expected revenues to be sufficient to fund operations to profitability.
• Advancing a best-in-class prefilled syringe for SYFOVRE with regulatory submission planned in 1H 2026.
• New five-year data from the GALE extension study demonstrated SYFOVRE delayed GA progression by approximately 1.5 years in patients with nonsubfoveal GA.

Risks

• Preliminary and unaudited financial figures are subject to completion of financial closing procedures and audit, and may differ materially from actual results.
• Actual results may differ materially from forward-looking statements due to various important factors, including market acceptance, clinical trial outcomes, and regulatory approvals.
• Uncertainty regarding whether clinical trial results for EMPAVELI, SYFOVRE, or future products will warrant regulatory submissions or if submissions will be made as anticipated.
• Risk that the company's products may not generate the projected revenues or achieve/maintain profitability.
• Risk that the company's cash resources, together with its projected revenues, may not fund its operations through profitability.
• SYFOVRE carries risks of endophthalmitis, retinal detachments, retinal vasculitis and/or retinal vascular occlusion (potentially leading to severe vision loss), increased rates of neovascular (wet) AMD, intraocular inflammation, and increased intraocular pressure.
• EMPAVELI increases the risk of serious, life-threatening, or fatal infections caused by encapsulated bacteria (e.g., Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B), even in vaccinated patients.
• EMPAVELI carries risks of systemic hypersensitivity reactions (e.g., facial swelling, rash, urticaria, pyrexia) and anaphylaxis.
• Patients discontinuing EMPAVELI treatment must be closely monitored for signs and symptoms of hemolysis and other reactions.
• EMPAVELI may interfere with silica reagents in coagulation panels, leading to artificially prolonged activated partial thromboplastin time (aPTT).
• EMPAVELI may cause embryo-fetal harm when administered to pregnant women, requiring effective contraception for females of reproductive potential.

Future Outlook

The company anticipates continued growth across its business, with a focus on expanding the geographic atrophy market and strengthening SYFOVRE's competitive position. EMPAVELI is expected to build towards blockbuster status. The company projects that its current cash and cash equivalents, combined with expected product revenues, will be sufficient to fund operations to profitability. Key pipeline advancements include a planned regulatory submission for a SYFOVRE prefilled syringe in 1H 2026, research availability of an AI imaging tool (OCT-F) in 2H 2026, topline data for SYFOVRE + APL-3007 in 2027, and an IND submission for APL-90993 in 2H 2026.

Management Comments

• "In 2025, we made significant strides across our business, translating focused execution into meaningful commercial and pipeline progress that positions us for strong momentum as we enter 2026." Cedric Francois, M.D., Ph.D., Chief Executive Officer.
• "As we look ahead, our priority is expanding the geographic atrophy market and advancing targeted initiatives to further strengthen SYFOVREs competitive position and long-term growth potential." Cedric Francois, M.D., Ph.D., Chief Executive Officer.
• "EMPAVELI continues to build toward blockbuster status, with more than 5% market penetration in C3G and primary IC-MPGN following its first full quarter post-launch." Cedric Francois, M.D., Ph.D., Chief Executive Officer.
• "With a strong balance sheet and growing commercial revenue base, we believe that we are well positioned to self-fund our pipeline and drive long-term sustainable value creation through disciplined financial execution." Cedric Francois, M.D., Ph.D., Chief Executive Officer.

Industry Context

Apellis Pharmaceuticals operates in the highly specialized biopharmaceutical sector, focusing on complement science to develop therapies for serious diseases. The success of SYFOVRE in geographic atrophy and EMPAVELI in rare kidney diseases positions Apellis as a leader in C3-targeting medicines. The company's strategic focus on expanding market share for SYFOVRE and advancing EMPAVELI towards "blockbuster status" reflects a competitive drive within the ophthalmology and rare disease markets, where innovation in complement inhibition is a key trend. The development of a prefilled syringe for SYFOVRE and an AI imaging tool (OCT-F) indicates a commitment to improving patient experience and diagnostic capabilities, aligning with broader industry trends in patient-centric care and technological integration.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, market leadership, pipeline advancements, and projected self-funding to profitability, potentially leading to increased shareholder value.
• Patients (SYFOVRE): Improved treatment options and convenience with the planned prefilled syringe, and potential for enhanced diagnostic tools (OCT-F) and next-generation therapies (SYFOVRE + APL-3007).
• Patients (EMPAVELI): Expanded access to treatment for C3G and primary IC-MPGN, and potential new therapies for FSGS and DGF, addressing high unmet medical needs.
• Employees: Positive outlook due to company growth and pipeline expansion, suggesting job stability and potential for further development.
• Healthcare Providers: New tools (OCT-F) and improved administration methods (prefilled syringe) for SYFOVRE, and expanded treatment options for rare kidney diseases with EMPAVELI.
• Regulatory Authorities: Ongoing engagement with regulatory bodies for new product submissions and indication expansions.

Next Steps

• Regulatory submission for SYFOVRE prefilled syringe in 1H 2026.
• Research use availability of OCT-F (AI imaging tool) in retina specialist practices in 2H 2026.
• Topline data from Phase 2 study of SYFOVRE + APL-3007 expected in 2027.
• Investigational New Drug (IND) submission for APL-90993 in 2H 2026.
• Continued commercial launch of EMPAVELI in C3G and primary IC-MPGN.
• Ongoing pivotal trials of EMPAVELI in FSGS and DGF.
• Corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.

Key Dates

Recommendation

The filing demonstrates robust commercial execution with significant revenue growth for both SYFOVRE and EMPAVELI, exceeding initial market penetration expectations for the latter. The company's strong cash position and clear path to self-funding profitability, coupled with a promising pipeline including a SYFOVRE prefilled syringe and new EMPAVELI indications, suggest strong future growth potential. The preliminary nature of the results is noted, but the overall trajectory and strategic clarity are highly favorable for long-term investors.

Keywords

Apellis Pharmaceuticals, APLS, SYFOVRE, EMPAVELI, pegcetacoplan, geographic atrophy, GA, C3 glomerulopathy, C3G, primary immune complex membranoproliferative glomerulonephritis, IC-MPGN, rare kidney diseases, complement cascade, ophthalmology, nephrology, biopharmaceutical, financial results, revenue, cash, pipeline, clinical trials, prefilled syringe, APL-3007, APL-90993, FcRn, FSGS, DGF